JPMorgan raised the firm’s price target on Erasca (ERAS) to $25 from $24 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology space.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
- Erasca price target raised to $20 from $12 at Guggenheim
- Erasca price target raised to $18 from $11 at Piper Sandler
- Erasca price target raised to $19 from $16 at Mizuho
- Erasca reports Q4 EPS (10c), consensus (11c)
- Erasca: Pan-RAS Data Momentum and Strategic Partnerships Underpin Upsized Revenue Outlook and Buy Rating